Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents: Difference between revisions
Jump to navigation
Jump to search
Line 13: | Line 13: | ||
==Overview== | ==Overview== | ||
Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel | ===Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents(DONOT EDIT)=== | ||
{{cquote| | |||
* Consider drug therapy in children >10 years of age (usually wait until menarche for females) and after a 6- to 12-month trial of fat- and cholesterol-restricted dietary management. | * Consider drug therapy in children >10 years of age (usually wait until menarche for females) and after a 6- to 12-month trial of fat- and cholesterol-restricted dietary management. | ||
Line 24: | Line 26: | ||
*** Minimal, LDL <3.35 mmol/L (130 mg/dL) | *** Minimal, LDL <3.35 mmol/L (130 mg/dL) | ||
*** Ideal, LDL <2.85 mmol/L (110 mg/dL) | *** Ideal, LDL <2.85 mmol/L (110 mg/dL) | ||
}} | |||
==References== | ==References== |
Revision as of 13:45, 29 October 2011
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Template:DiseaseDisorder infobox
WikiDoc Resources for Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
|
Guidelines / Policies / Govt |
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents(DONOT EDIT)
“ |
|
” |